Aimmune Therapeutics Inc  

(Public, NASDAQ:AIMT)   Watch this stock  
Find more results for AIMT
35.76
+0.18 (0.52%)
Real-time:   11:52AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.41 - 35.92
52 week 15.97 - 37.50
Open 35.50
Vol / Avg. 46,276.00/778,725.00
Mkt cap 1.82B
P/E     -
Div/yield     -
EPS -2.34
Shares 50.86M
Beta     -
Inst. own 86%
Dec 1, 2017
Aimmune Therapeutics, Inc. - Special Call - 8:00AM EST - Add to calendar
Nov 28, 2017
Aimmune Therapeutics Inc at Piper Jaffray Healthcare Conference - 12:30PM EST - Add to calendar
Nov 7, 2017
Aimmune Therapeutics Inc at Credit Suisse Healthcare Conference - Webcast
Oct 16, 2017
Aimmune Therapeutics Inc Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi's Dupilumab for Peanut Allergy Call - Webcast
Sep 26, 2017
Aimmune Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 15, 2017
Aimmune Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference - Webcast
Sep 8, 2017
Aimmune Therapeutics Inc at BioCentury NewsMakers in the Biotech Industry Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -52.05% -31.62%
Return on average equity -57.01% -32.84%
Employees 122 -
CDP Score - -

Address

8000 Marina Blvd Ste 300
BRISBANE, CA 94005-1884
United States - Map
+1-650-6145220 (Phone)
+1-650-6160075 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

Officers and directors

Mark D. McDade Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Stephen G. Dilly M.D. Ph.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Eric H. Bjerkholt Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Jeffrey H. Knapp Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Susan E. Barrowcliffe Senior Vice President, General Manager of Europe
Age: 59
Bio & Compensation  - Reuters
Mary M. Rozenman Senior Vice President - Strategy and Corporate Development
Age: 36
Bio & Compensation  - Reuters
Douglas T. Sheehy J.D. General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Sue Barrowcliffe General Manager of Europe
Bio & Compensation  - Reuters
Daniel C. Adelman M.D. Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Greg Behar Independent Director
Age: 47
Bio & Compensation  - Reuters